Edgewise Therapeutics Quarterly Balance Sheet
NASDAQ: EWTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Edgewise Therapeutics financial position
As of Jun 30, 2026, Edgewise Therapeutics reported total assets of $479.7 million, down 21.8% from a year earlier against total liabilities of $31.6 million. Shareholders' equity stood at $448.1 million, or 93.4% of assets. The company held $72.3 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 16.24, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Edgewise Therapeutics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 72.32M | 33.21M | 61.15M | 46.00M | 43.40M | 49.92M | 41.67M | 44.81M | 43.48M | 30.26M | 86.10M | 32.96M |
| Total Current Assets | 471.52M | 509.79M | 543.38M | 573.90M | 603.25M | 443.18M | 475.48M | 499.44M | 519.44M | 541.43M | 327.00M | 297.92M |
| Property, Plant & Equipment | 6.89M | 7.40M | 7.83M | 8.13M | 8.60M | 8.99M | 9.50M | 9.97M | 9.90M | 10.18M | 10.44M | 10.68M |
| Total Assets | 479.69M | 518.52M | 552.60M | 583.47M | 613.33M | 454.39M | 486.82M | 511.28M | 531.65M | 553.81M | 340.04M | 311.36M |
| Accounts Payable | 4.67M | 7.29M | 6.01M | 6.16M | 8.32M | 8.79M | 5.58M | 5.65M | 6.80M | 4.72M | 4.03M | 5.32M |
| Total Current Liabilities | 29.04M | 22.54M | 27.37M | 21.65M | 20.90M | 21.11M | 23.86M | 18.96M | 17.18M | 14.60M | 16.77M | 16.34M |
| Total Liabilities | 31.61M | 25.32M | 30.35M | 24.82M | 24.26M | 24.67M | 27.60M | 22.41M | 21.17M | 18.86M | 21.20M | 20.94M |
| Shareholders' Equity | 448.08M | 493.20M | 522.26M | 558.65M | 589.07M | 429.72M | 459.22M | 488.88M | 510.47M | 534.94M | 318.83M | 290.43M |
| Retained Earnings | -652.71M | -595.38M | -546.37M | -496.15M | -455.49M | -419.37M | -378.58M | -338.91M | -304.79M | -273.29M | -244.76M | -214.62M |
| Net Cash (Debt) | 72.32M | 33.21M | 61.15M | 46.00M | 43.40M | 49.92M | 41.67M | 44.81M | 43.48M | 30.26M | 86.10M | 32.96M |
| Shares Outstanding | 107.78M | 107.48M | 106.25M | 105.76M | 105.34M | 95.21M | 94.84M | 94.41M | 93.64M | 93.28M | 70.45M | 63.46M |
This table shows 12 quarterly periods of Edgewise Therapeutics's balance sheet, from Q2 2026 back to Q3 2023, across 14 line items including cash & equivalents, total current assets, property, plant & equipment. Values in USD; B = billions, M = millions. Fiscal periods follow EWTX's reporting calendar. What is a balance sheet?